Through the official letter n° 63, Department of Surveillance Prevention and Control of STI, HIV/AIDS and Viral Hepatitis, the Ministry of Health answered to the letter sent by FOAESP, GIV and RNP+SP on November 23 and published here on November 29.
On the Official Letter from November 30, the Ministry explains that the updated of the estimated data of hepatitis C in Brazil were conclude in partnership with Pan American Heath Organization (PAHO) and by the CDA (Center for Diseases Analysis), and, among the frameworked actions, it have been reassured the intention of treating every people carrying HCV in Brazil. Check the following document.
Circular letter nº
63-SEI/2017/COVIG/CGVP/DIAHV/SVS/MS
Brasília, November 30, 2017.
Addressed to the FOAESP, GIV and RNP+SP: Civil Society representatives
São Paulo, SP
Subject: Response to the FOAESP, GIV, and RNP+SP: Civil Society representatives.
Estimated members,
1. The Ministry of Health in
partnership with the PAHO/Washington and the CDA (Center for Diseases Analysis),
took the initiative of updating, through developing a new Mathematical Model, the
estimated epidemiological data on the epidemic of Hepatitis C in Brazil, aiming
at improving care actions, prevention and treatment campaigns in our country. Part
of that database have passed ahead preliminarily at the 11° Congress on
HIV/AIDS and the 4° Congress on Viral Hepatitis. According to these results, it is estimated the prevalence of serum reagents
(anti- HCV) in Brazil, is 0,7% approximately, which corresponds to
approximately 1.032.000 HCV-seropositive individuals in Brazil. These individuals have been exposed to the
virus but not necessarily have infected.
According to the surveillance data, it is
estimated that 656.000 people are viremic and really in need of treatment. It
is important to reinforce that it is estimated that the 0,7% prevalence refers
to general population age 15 to 69, until 2016. The estimated surveillance data were elaborated on the basis of several Ministry
of Health sectors database, publications and periodicals in the last five
years, Anvisa’s blood donors database, conscript diagnosis studies, among
others. For analysis, these data were compilated and validated with the
collaboration of Brazilian researchers who make up the Technical Advisory
Committee on Viral Hepatitis, technical staffs of the Ministry of Health from
the PAHO and the CDA.
2. Based on the estimates above, it
is observed the need of adding all efforts on identifying HCV-infected people, amplifying
the distribution and undertaking HCV testing. Taking by consider that hepatitis C is a
silent disease, it is crucial to vest in communications strategy, reinforcing
the need of people age 40 or more to go after a healthcare service for advice
as soon as possible.
3. Since 2011 the Ministry of Health
purchased approximately 15 million HCV rapid tests. At the same time, the DIHV has
prepared the Hepatitis C Elimination Plan, already adopted by the Tripartite Interagency
Committee, which aimed to broad
diagnosis, notification and treatment of hepatitis C. In order to meet demands the
action developments are going to be articulated over the three Brazilian power
instances, the Civil Society Organization, among other political actors.
4. Progressively the tratamentos are
becoming more efficient and simplified, they are presenting less side effects
day by day and the cure rate is increasing. The Ministry of Health is putting great
effort on keeping tracking of technology innovations and, on December 4, 2017,
announced to be registered two new drugs on the treatment of hepatitis C.
Reinforcing through this action, its commitment on the treatment of every HCV
infected person, promise made by the Ministry of Health, at the World Hepatitis
Summit 2017, in São Paulo, Brazil. The access to treatment will happen
independently on the fibrosis stage. It is worth to note that from 2015 until
now, the Ministry of Health provided around 63.838 treatments with the new direct
acting antiviral drugs.
5. Regarding to coinfected people, the Clinical
and Therapeutic Guidelines for Hepatitis C and Coinfection, prioritized treatment
for those people, independently of the
liver fibrosis stage.
6. We are thankful for the collaboration
and opportunity of discussion and we place ourselves at disposal for further clarification.
Regards,
Adele Schwartz Benzaken
Headmistress of the Department of Surveillance
Prevention and Control of STI, HIV/AIDS and Viral Hepatitis
(Document electronically signed)
Nenhum comentário:
Postar um comentário